97 related articles for article (PubMed ID: 28407529)
1. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
Adam R; Yi B; Innominato PF; Barroso E; Laurent C; Giuliante F; Capussotti L; Lapointe R; Regimbeau JM; Lopez-Ben S; Isoniemi H; Hubert C; Lin JK; Gruenberger T; Elias D; Skipenko OG; Guglielmi A;
Eur J Cancer; 2017 Jun; 78():7-15. PubMed ID: 28407529
[TBL] [Abstract][Full Text] [Related]
2. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens.
Truant S; Séquier C; Leteurtre E; Boleslawski E; Elamrani M; Huet G; Duhamel A; Hebbar M; Pruvot FR
HPB (Oxford); 2015 Feb; 17(2):176-84. PubMed ID: 25041611
[TBL] [Abstract][Full Text] [Related]
3. Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis.
Sugiyama M; Uehara H; Shin Y; Shiokawa K; Fujimoto Y; Mano Y; Komoda M; Nakashima Y; Sugimachi K; Yamamoto M; Morita M; Toh Y
Surg Today; 2022 Apr; 52(4):633-642. PubMed ID: 34762175
[TBL] [Abstract][Full Text] [Related]
4. Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases.
Conrad C; Vauthey JN; Masayuki O; Sheth RA; Yamashita S; Passot G; Bailey CE; Zorzi D; Kopetz S; Aloia TA; You YN
Ann Surg Oncol; 2017 Dec; 24(13):3857-3864. PubMed ID: 28929463
[TBL] [Abstract][Full Text] [Related]
5. Liver resection and ablation for metastatic melanoma: A single center experience.
Doussot A; Nardin C; Takaki H; Litchman TD; D'Angelica MI; Jarnagin WR; Postow MA; Erinjeri JP; Kingham TP
J Surg Oncol; 2015 Jun; 111(8):962-8. PubMed ID: 26073980
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer.
Bartolini I; Ringressi MN; Melli F; Risaliti M; Brugia M; Mini E; Batignani G; Bechi P; Boni L; Taddei A
Gastroenterol Res Pract; 2018; 2018():5353727. PubMed ID: 30116264
[TBL] [Abstract][Full Text] [Related]
7. ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection.
Torén W; Sasor A; Ansari D; Andersson R
Anticancer Res; 2024 Jun; 44(6):2597-2604. PubMed ID: 38821620
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Resection for Synchronous Colorectal Liver Metastasis: the New Standard of Care?
Abelson JS; Michelassi F; Sun T; Mao J; Milsom J; Samstein B; Sedrakyan A; Yeo HL
J Gastrointest Surg; 2017 Jun; 21(6):975-982. PubMed ID: 28411351
[TBL] [Abstract][Full Text] [Related]
9. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S; Rosati G; Nasti G; Lonardi S; Zaniboni A; Marchetti P; Leone F; Bilancia D; Iaffaioli RV; Zagonel V; Giordano M; Corsi DC; Ferraú F; Labianca R; Ronzoni M; Scartozzi M; Galli F;
Eur J Cancer; 2017 Sep; 83():106-115. PubMed ID: 28735067
[TBL] [Abstract][Full Text] [Related]
10. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
11. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
Rivera F; Karthaus M; Hecht JR; Sevilla I; Forget F; Fasola G; Canon JL; Guan X; Demonty G; Schwartzberg LS
Int J Colorectal Dis; 2017 Aug; 32(8):1179-1190. PubMed ID: 28424871
[TBL] [Abstract][Full Text] [Related]
12. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
Gouverneur A; Salvo F; Berdaï D; Moore N; Fourrier-Réglat A; Noize P
J Geriatr Oncol; 2018 Jan; 9(1):15-23. PubMed ID: 28844343
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Modest DP; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Scheithauer W; Moehler M; Westphalen CB; Holch JW; von Einem JC; Held S; Heinemann V;
Eur J Cancer; 2017 Oct; 84():262-269. PubMed ID: 28843184
[TBL] [Abstract][Full Text] [Related]
15. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial.
Rouanet P; Rullier E; Lelong B; Maingon P; Tuech JJ; Pezet D; Castan F; Nougaret S;
Dis Colon Rectum; 2017 Jul; 60(7):653-663. PubMed ID: 28594714
[TBL] [Abstract][Full Text] [Related]
16. Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.
Groot Koerkamp B; Sadot E; Kemeny NE; Gönen M; Leal JN; Allen PJ; Cercek A; DeMatteo RP; Kingham TP; Jarnagin WR; D'Angelica MI
J Clin Oncol; 2017 Jun; 35(17):1938-1944. PubMed ID: 28426374
[TBL] [Abstract][Full Text] [Related]
17. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.
Renfro LA; Goldberg RM; Grothey A; Sobrero A; Adams R; Seymour MT; Heinemann V; Schmoll HJ; Douillard JY; Hurwitz H; Fuchs CS; Diaz-Rubio E; Porschen R; Tournigand C; Chibaudel B; Hoff PM; Kabbinavar FF; Falcone A; Tebbutt NC; Punt CJA; Hecht JR; Souglakos J; Bokemeyer C; Van Cutsem E; Saltz L; de Gramont A; Sargent DJ;
J Clin Oncol; 2017 Jun; 35(17):1929-1937. PubMed ID: 28414610
[TBL] [Abstract][Full Text] [Related]
18. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Lévi F; Karaboué A; Saffroy R; Desterke C; Boige V; Smith D; Hebbar M; Innominato P; Taieb J; Carvalho C; Guimbaud R; Focan C; Bouchahda M; Adam R; Ducreux M; Milano G; Lemoine A
Br J Cancer; 2017 Sep; 117(7):965-973. PubMed ID: 28817838
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]